Clinical trial on Efficacy and Safety of the Next-generated intrapleural hyperthermic chemotherapy for thoracic malignancies with dissemination and malignant pleural effusions - Phase II study of next-generated intrapleural hyperthermic chemotherapy for thoracic malignancies

niversity of Miyazaki Hospital Department of Surgery II0 个研究点目标入组 30 人开始时间: 2014年10月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)symptomatic brain metastasis 2)the complications (hemoptysis >= 2.5ml of fresh blood, arterial thromboembolism (brain infarction, temporarily ischemic attack, myocardial infarction, angina pectoris), venous thoromboembolism (deep vein thromboembolism, pulmonary embolism), uncontrollable hypertension, intestinal perforation, severe fistula, broncho-esophageal fistula, intraabdominal inflammation, congenital bleeding tendency, abnormality of blood coagulation, uncontrollable diabetic mellitus, infection, active intestinal pneuminitis 3)surgery within 28 days (except for lung cancer) 4)scheduled thoracic irradiation during bevasizumab treatment 5)symptomatic cardiac tamponade 6)needs to receive an emergency irradiation due to supra vena cava syndrome 7)active pneumonia and intestinal pneumonitis displayed by chest X-ray/chest computed-tomographic examination 8)difficult to enroll because of complication with psychosomatic disease or mental symptomati problems 9)Others. Patients judged for inappropriation by attending physician or lead principal investigator

发起方

niversity of Miyazaki Hospital Department of Surgery II